萬泰生物(603392.SH):與養生堂擬簽訂技術許可成本分攤協議
格隆匯 3 月 25日丨萬泰生物(603392.SH)公佈,2019年1月,公司的控股股東養生堂(代表養生堂自身、包括公司及廈門萬泰滄海生物技術有限公司(“萬泰滄海”)在內的養生堂5家子公司、以及廈門大學養生堂生物藥物聯合實驗室合計7家機構,以下合稱“被許可方”)與西格瑪-奧德里奇(上海)貿易公司(默克集團旗下公司)簽署了有關於CHOZN®ZFN-修飾細胞系(宿主細胞株)的《CHOGS買賣協議》,獲得CHOZN®ZFN-修飾細胞系宿主細胞株的樣本以及在中國境內的使用許可,被許可方有權以“研發許可”和“商業許可”方式使用CHOZN®ZFN-修飾細胞系宿主細胞株。CHOGS協議簽署後,公司尚未實際使用CHOZN®ZFN-修飾細胞系宿主細胞株進行技術研發活動,亦未實際承擔及支付相關許可費。
鑑於公司(包括公司及子公司萬泰滄海)後續擬將CHOZN®ZFN-修飾細胞系宿主細胞株應用於公司診斷類及預防類產品的研發製造;而養生堂將繼續進行CHOZN®ZFN-修飾細胞系宿主細胞株在治療性藥物及其相關通用技術領域的應用技術研發,並擬單獨或與其他被許可方之間共同進行其他技術或產品的研發。考慮到養生堂與公司之間就相互各自的產品研發和生產經營做出的避免同業競爭安排,養生堂與公司經協商後擬簽訂《技術許可成本分攤協議》,就CHOZN®ZFN-修飾細胞系宿主細胞株的使用範圍領域和許可費分攤等事宜進行約定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.